Abstract 4668
Background
Long-term survival is poor for patients with locally advanced or metastatic urothelial carcinoma (UC) receiving chemotherapy and/or immunotherapy following progression with platinum-containing chemotherapy. Genetic alterations of fibroblast growth factor receptors (FGFR) have been shown to play a role in UC development and progression. Non-genetic and epigenetic activation of FGFR gene expression have also been described. Rogaratinib, an oral pan-FGFR 1-3 inhibitor, has shown promising activity and a manageable safety profile in a phase I study in patients with UC who were selected based on FGFR1-3 mRNA overexpression and/or activating mutations in the FGFR3 gene.
Trial design
This is a randomized, open-label, phase 2/3 study to evaluate the efficacy and safety of rogaratinib compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic UC who have received prior platinum-containing chemotherapy. The primary objective is to show superiority of rogaratinib over chemotherapy in prolonging overall survival (OS) of UC patients with FGFR-positive tumors. Secondary objectives include: objective response rate (ORR), progression-free survival, disease control rate, duration of response, and safety. Testing for FGFR1 and 3 mRNA over expression will be conducted centrally using an RNA in situ hybridization (RNA-ISH) in archival samples. Eligible patients will be randomized 1:1 to rogaratinib (800 mg po bid) or iv chemotherapy Q3W (docetaxel 75 mg/m2; paclitaxel 175 mg/m2; or 320 mg/m2 vinflunine). Randomization will be stratified according to PIK3CA and/or RAS activating mutations, prior immunotherapy, and modified 4-factor Bellmunt risk score. The objective for the phase 2 part of the study is ORR. A total of 116 patients in PIK3CA and RAS WT patients will be enrolled to the phase 2 part of the study to rule out a low difference in ORR between rogaratinib and chemotherapy as futility. The phase 3 portion of the study is powered to detect an increase in median OS in PIK3CA and RAS WT patients. Total patient enrollment expected to be approximately 400 patients.
Clinical trial identification
NCT03410693.
Legal entity responsible for the study
Bayer AG.
Funding
Bayer AG.
Editorial Acknowledgement
Disclosure
K. Nakajima, C. Lu, A. Holynskyj: Bayer employment. All other authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract